RegisterLogin

SDZ 224-015

CAT: 0804-HY-141622-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-141622-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting Mpro (IC50 of 30 nM) [1][2].
CAS Number
[161511-45-1]
UNSPSC
12352005
Target
Caspase; Interleukin Related; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/sdz-224-015.html
Purity
96.05
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(OCC1=CC=CC=C1)N[C@@H](C(C)C)C(N[C@@H](C)C(N[C@@H](CC(OCC)=O)C(COC(C2=C(C=CC=C2Cl)Cl)=O)=O)=O)=O
Molecular Formula
C30H35Cl2N3O9
Molecular Weight
652.52
References & Citations
[1]Martin A Redhead, et al. Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19. Sci Rep. 2021 Jun 24;11 (1) :13208.|[2]P R Elford, et al. Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115 (4) :601-6.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-1

Related Products

CatalogName
HY-103179SDZ-WAG994
HY-113907SDZ-285604
HY-116309SDZ 216-525
HY-13059-01SDZ 220-581
HY-16149SDZ-CPI 975
HY-19029SDZ 208-912
HY-19150SDZ-FOX-988
HY-108480-01SDZ NKT 343
HY-19036SDZ NVI 085
HY-103143ASDZ 205-557

Alternative Products

CatalogName
MBS5785041SDZ 224-015
MBS3601950-01HUHS-015
TRC-J211350-1MGJWH-015
A3692-1000OTX-015
M18553-01PFK-015
T70537-01DC 015
TRC-H673490-250MGHUHS 015
B5094-1JWH 015
T9901A-1671-01ABC-015

Popular Products